Skip to content
TrialScanner

NCT04713514

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Phase 2CompletedMRKCollaborator

Registry record

Lead sponsor
ARCAGY/ GINECO GROUP
Conditions
Platinum-sensitive Ovarian Cancer; Relapsed Ovarian Cancer
Primary completion
Dec 15, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04713514 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

2 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04713514: OSE2101 Alone or in Combinati... | TrialScanner